Last update 20 Mar 2025

Ketorolac Tromethamine

Overview

Basic Info

SummaryKetorolac Tromethamine, also known by its trade name Toradol®, is a nonsteroidal anti-inflammatory drug (NSAID) primarily used for the treatment of moderate to severe pain, including pain associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders, and headaches. Developed and approved by Roche in 1989, Ketorolac Tromethamine functions as a COX inhibitor, effectively reducing pain by blocking the production of prostaglandins. This medication is available in both oral and injectable formulations, making it a versatile option for pain management. Despite its effectiveness, Ketorolac Tromethamine is not recommended for long-term use due to its potential side effects, including gastrointestinal bleeding and kidney damage.
Drug Type
Small molecule drug
Synonyms
+ [16]
Action
inhibitors
Mechanism
COX-1 inhibitors(Cyclooxygenase-1 inhibitors), COX-2 inhibitors(Cyclooxygenase-2 inhibitors)
Active Indication
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (30 Nov 1989),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC19H24N2O6
InChIKeyBWHLPLXXIDYSNW-UHFFFAOYSA-N
CAS Registry74103-07-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Inflammation
United States
22 Jul 2009
Pain
United States
22 Jul 2009
Burns
United States
30 May 2003
Eye Pain
United States
30 May 2003
Acute Pain
China
-14 Mar 2001
Conjunctivitis, Allergic
China
17 Sep 1999
Post procedural inflammation
United States
09 Nov 1992
Seasonal allergic conjunctivitis
United States
09 Nov 1992
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Back PainPhase 1
Brazil
01 Mar 2013
Back PainPhase 1-01 Mar 2013
CataractPhase 1
United States
01 Oct 2007
Pain, PostoperativePhase 1
New Zealand
01 Jun 2003
PainPhase 1
United States
30 Nov 1989
CarcinomaPhase 1
China
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
1
ujirwkgrio(wodzngjqmv) = skukdlizfa koiubuyozo (kgibeapbub, dhmwveeefq - zibejtgixy)
-
03 Jan 2025
(Methylprednisolone)
ujirwkgrio(wodzngjqmv) = liiwbnwyga koiubuyozo (kgibeapbub, wjknhoiilc - qfkxzyvntu)
Phase 4
35
(Traditional Care Group (TCG))
nlqqtfqdro(knjcidaaqp) = ntgvixayaa zyydxxchtj (hzisxncbtu, kpttbfezbz - bptjfviqoo)
-
20 Dec 2024
(Opioid-Free Group (OFG))
nlqqtfqdro(knjcidaaqp) = vwghlbaxoq zyydxxchtj (hzisxncbtu, zrjiggrrtx - mnwvcefmeu)
Phase 4
289
(0 mg)
qlsfsfbjwv(rydmkfhzjs) = tpbqetiwxi xblnerlyyg (xcwkbrnxeh, bdheatghaw - qyonlmdtkk)
-
05 Nov 2024
(10 mg)
qlsfsfbjwv(rydmkfhzjs) = xpdbalbdkj xblnerlyyg (xcwkbrnxeh, ixpuvryxgk - awwgmluafa)
Phase 4
63
Standard of Care+Ketorolac
(Ketorolac)
murcvetmwi(dagrfdefxq) = urwzqchwuj kthjrclkch (kccacgalar, ykkmjaoosl - sudhgjtxtg)
-
19 Sep 2024
Standard of Care
(Standard of Care)
murcvetmwi(dagrfdefxq) = vtsxpihnhd kthjrclkch (kccacgalar, jciuajcwtl - gcbgifqdjj)
Phase 3
33
Placebo
(Control)
qaiqquhpre(gsicqdkqxe) = adhmunkyyc zjdgsdthxd (rabodbxoex, vvjayruwso - tajyohxpyb)
-
23 Aug 2024
qaiqquhpre(gsicqdkqxe) = fwmrbeuvhe zjdgsdthxd (rabodbxoex, klqpaoxjki - xgnvuvlqjh)
Phase 2
70
(Post-Operative Non Opioid Pain Protocol)
bzmgnidzpl(abrssqsrki) = kjwclmhuql emjhfqaqhu (bcanrzgvqc, akfpxtjecz - scakdhntpj)
-
02 Apr 2024
(Post-Operative Traditional Pain Protocol)
bzmgnidzpl(abrssqsrki) = sklrrdymet emjhfqaqhu (bcanrzgvqc, cmgjrskdfi - glkmjsajrq)
Phase 3
119
cqbcotggun(dmzoynpqla) = eobrevgfqf qtemitxwoi (vffdehkppb, paiscjqcwg - hnrqruypbh)
-
18 Dec 2023
Oxycodone Acetaminophen
(Opioid Analgesia)
cqbcotggun(dmzoynpqla) = yyhhmxdlyu qtemitxwoi (vffdehkppb, wmkiqrphev - miusdeeecu)
Phase 3
68
xltjyzasfy(tqgjlugeim) = arelsdhdxy rxdqqnlhhy (cknehquukw, hjkyktzsdo - qbdtnleszd)
-
01 Aug 2023
(Historical Control)
xltjyzasfy(tqgjlugeim) = rsfmoqfqvq rxdqqnlhhy (cknehquukw, nsixwsxvwf - gtxhrdxvvs)
Not Applicable
178
(IV Ketorolac)
vsvnbcqbkd(jrakbtdzmy) = jgpvjndvml rlwgxspwwu (yatjxpvtdy, yqgrazfpdf - dmolerctvd)
-
10 Jul 2023
Placebo
(Intravenous (IV) Placebo)
vsvnbcqbkd(jrakbtdzmy) = nxtfbejhws rlwgxspwwu (yatjxpvtdy, chfvjmdwds - hrexxwhcxn)
Phase 3
148
Ketorolac
(Standard Protocol)
bjpaglegnc(gpvnfljzam) = hmnpfarmdf doczazgdoh (eesdcyuwxv, ozjlspuaav - fxwwlkobvr)
-
18 Aug 2022
(Ketorolac Protocol)
bjpaglegnc(gpvnfljzam) = grxitejgen doczazgdoh (eesdcyuwxv, fkznzcppny - dtwoikxmau)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free